Flputnam Investment Management Co. Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Flputnam Investment Management Co. bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 2,761 shares of the biopharmaceutical company’s stock, valued at approximately $831,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALNY. Geode Capital Management LLC increased its position in Alnylam Pharmaceuticals by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after acquiring an additional 151,480 shares during the period. Norges Bank acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $895,816,000. Orbis Allan Gray Ltd raised its holdings in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares in the last quarter. Legal & General Group Plc raised its stake in Alnylam Pharmaceuticals by 8.3% during the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock worth $382,339,000 after acquiring an additional 73,716 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 23.6% during the 4th quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after purchasing an additional 175,951 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.8%

ALNY stock opened at $224.60 on Tuesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The stock has a market capitalization of $30.05 billion, a price-to-earnings ratio of 41.75 and a beta of 0.30. The business’s fifty day moving average price is $271.51 and its two-hundred day moving average price is $300.10. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company’s quarterly revenue was up 66.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.51) EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of research analyst reports. HC Wainwright cut their price target on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a report on Friday, July 31st. Morgan Stanley decreased their price target on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a report on Friday, July 31st. Stifel Nicolaus decreased their price objective on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Oppenheimer lowered their target price on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Finally, Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $393.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.